Results 121 to 130 of about 5,483 (267)

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In patients with drug‐resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real‐time biomarkers.
Zachary T. Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R. Henry, David P. Darrow, Michael C. Park, Theoden I. Netoff, Robert A. McGovern   +10 more
wiley   +1 more source

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort

Epilepsia, EarlyView.
Abstract Objective Status epilepticus (SE) treatment is more effective when benzodiazepines (BZDs) are given soon after SE diagnosis. The Quality Improvement in Time to Treat Status Epilepticus (QuITT‐SE) trial is a multicenter, randomized, stepped‐wedge effectiveness‐implementation hybrid study aimed at improving time to SE treatment.
Adam P. Ostendorf, Gabrielle Brown‐Mitchell, Tobias Loddenkemper, Lindsey A. Morgan, Brian Appavu, Raquel Farias‐Moeller, Dana Harrar, Craig Press, Janette Mailo, Nicholas S. Abend, William D. Gaillard, Shasha Bai, Mariah Eisner, Emily Kroshus, Kathryn Vannatta, Howard P. Goodkin, on behalf of the QuITT‐SE Study Group, Karen Allen, Megan Fredwall, Allison Nelson, Megan Rose, Corinne McCabe, Hannah Lehmann, Jared Haught, Lauren McHenry, William Korab, Amanda Courtney, Angela Turner, Coral Crandell, Sophie Rotter‐Aboyoun, Zoe Munsey, Mikaela Morales, Jacqueline Lee‐Eng, Sahar Rostamian, Elijah Simon, Luisa Fernanda Atunes Ortega, Alyssa Chen, Kristin Reid, Heather Kennedy, Courtney Englehardt, Jensen Kuchrawy, Abigail Howe, Nora Reilly, Lora Pixley, Amy Liljestrand, Annalee Antonetty, Agnieszka Kielian, Jennifer Gettings, Lillian Voke, Shannon Manzi, Lauren Fleser, Jeffrey Bolton, Madeline Chiujdea, Deborah Shiers, Michele Jackson, Stephanie Dailey, Lynn McDaniel, Jared Barkes, Brittany Dunn, Laure Cromwell, Irene Kelly, Kimberlee Meegan, Anne Vasiliadis, Julia S. Keenan, Sarah Vepraskas, Ronda Werner, Kimberly Zimmanck, Rupa Nallamothu, Sarah Otterson, Kaley Marrari, Lalaine Dungca, Nigel Negm, Sarah Kiel, Chris Kennie‐Richardson, Ariel Hierhozer, Katherine Dyer, Meera Singavi, Molly Green, Nate Evans, Caitlin Keiter, Jessica Johnson, Sara Molisani, Darshana Parikh, Veronica Zielinkski, Rachael Huber, Brody Giblin, Allix Edsill, Jessica Zook   +87 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

Epilepsia, EarlyView.
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome or Lennox‐Gastaut syndrome. Abstract Objective Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an ...
Antonio Gil‐Nagel, Kelly G. Knupp, Boudewijn Gunning, Domenica Immacolata Battaglia, Elizabeth A. Thiele, Ingrid E. Scheffer, An‐Sofie Schoonjans, Rima Nabbout, Nathalie Villeneuve, Kerstin Alexandra Klotz, Nicola Specchio, Rocio Sanchez‐Carpintero, Marta Zolnowska, Anne‐Liv Schulz, Lily Perrin, Najla Dickson, Mélanie Langlois, Amélie Lothe, Joseph Sullivan   +18 more
wiley   +1 more source

Metrology for Indoor Radon Measurements and Requirements for Different Types of Devices. [PDF]

Sensors (Basel)
Tsapalov A, Kovler K.
europepmc   +1 more source

Stereo‐electroencephalography–guided responsive neuromodulation: A propensity‐matched cohort study

Epilepsia, EarlyView.
Abstract Objective The optimal pre‐implantation evaluation and surgical targeting strategies for responsive neurostimulation (RNS) in patients with unresectable, drug‐resistant focal epilepsy continue to be debated. Although stereo‐electroencephalography (sEEG) is central to characterizing the seizure‐onset zone, its role in preoperative testing for ...
David Botros, Julian Brown, John D. Rolston, Paul A. House, Amir Arain, Matthew Jensen, Blake Newman, Brian Johnson, Sindhu Richards, Angela Peters, Shervin Rahimpour, Ben Shofty   +11 more
wiley   +1 more source

Are solid state nuclear track detectors truly integrated devices?-experimental evidence in radon measurements. [PDF]

Radiat Prot Dosimetry
Wasikiewicz JM.
europepmc   +1 more source

Effect of time to palliative epilepsy surgery on outcomes

Epilepsia, EarlyView.
Abstract Objective Epilepsy duration is a modifiable risk factor in the outcome of definitive epilepsy surgery; however, an analogous effect in palliative procedures has not been shown. We reviewed the Pediatric Epilepsy Surgery Database data for an association between epilepsy duration and seizure reduction in palliative procedures.
Robert M. Crutcher, David E. Horvat, Avery R. Caraway, Kristen H. Arredondo, Taylor J. Abel, Nitin Agarwal, Allyson L. Alexander, Dallas Michael Armstrong, Kurtis I. Auguste, Danilo Bernardo, Jeffrey Bolton, David Bonda, Dewi Frances Depositario‐Cabacar, Krista Eschbach, William D. Gaillard, Aran Groves, Jason S. Hauptman, Pradeep K. Javarayee, Cemal Karakas, Andrew T. Knox, Jenny J. Lin, Patricia E. McGoldrick, Derryl J. Miller, Edward John Novotny, Adam P. Ostendorf, Pilar D. Pichon, Shilpa B. Reddy, Debopam Samanta, Rani K. Singh, Janelle L. Wagner, Steven M. Wolf, Lily C. Wong‐Kisiel, Fernando N. Galan, M. Scott Perry, Michael A. Ciliberto   +34 more
wiley   +1 more source

Strategy and Metrological Support for Indoor Radon Measurements Using Popular Low-Cost Active Monitors with High and Low Sensitivity. [PDF]

Sensors (Basel)
Tsapalov A, Kovler K, Bossew P.
europepmc   +1 more source